Naloxone hydrochloride was synthesized in 1960 and is a derivative of hydroxy(dihydro)ketomorphine. Naloxone is an opioid receptor antagonist and was initially used to counteract opioid overdose. It has the specific effect of reversing respiratory depression and inducing awakening. It is a highly effective antidote for opioid overdose and a diagnostic drug for morphine and heroin dependence. Based on studies of the physiological effects of endogenous opioid-like substances, clinical researchers have not only used naloxone to antagonize respiratory depression caused by opioid drugs but have also conducted trials on stress-related diseases such as non-anesthetic drug overdose (ethanol, benzodiazepines), shock, cerebral infarction, and neonatal asphyxia syndrome, achieving good therapeutic results and generating great interest among doctors both domestically and internationally. In recent years, clinicians at home and abroad have also used it for the treatment of acute alcohol and sedative poisoning, hepatic encephalopathy, cerebral infarction, post-asphyxial ischemic encephalopathy in neonates, severe heatstroke, acute and chronic respiratory failure, and various critical conditions, with good results.
Packaging： 1000 vials/case
Specifications： 1ml:0.4mg, 2ml:2mg
Shelf Life： 30 months
Approval Number： 国药准字H20065189 国药准字H20065190
Indications： This product is an opioid receptor antagonist. It is used for the following purposes: 1) To antagonize respiratory depression caused by opioid drugs in postoperative anesthesia and promote patient awakening. 2) To completely or partially reverse respiratory depression caused by opioid overdose. 3) To rescue acute ethanol poisoning. 4) To diagnose acute opioid overdose.
Detail
1. Widely used opioid receptor antagonist in clinical practice.
2. First-choice drug for rescuing acute poisoning from sedatives and hypnotics.
3. First-choice drug for rescuing severe shock.
4. Effective in reversing central depression and promoting rapid awakening.
5. Non-addictive and not classified as a restricted anesthetic drug.
6. Covered by national medical insurance (Category A).
